TEL AVIV - SciSparc Ltd. (NASDAQ:SPRC), a specialty pharmaceutical company, announced today the completion of its core-technology patent process in several European countries. The patent, which relates to cannabinoid and n-acylethanolamine combinations, has been granted and validated in 14 European jurisdictions, including Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein, and the United Kingdom.
This recent patent approval enhances SciSparc's intellectual property portfolio, supporting the company's innovative technologies. The patent specifically covers compositions and methods aimed at potentiating therapeutic effects and reducing side effects of specific cannabinoids originally found in cannabis plants.
SciSparc's proprietary technology focuses on the safety enhancement of cannabinoids by utilizing low dosages of active components while still preserving their therapeutic benefits. This approach is part of the company's broader strategy to develop treatments for disorders and rare diseases affecting the central nervous system.
The company's drug development programs include SCI-110 for Tourette Syndrome, SCI-160 for pain management, and SCI-210 for Autism Spectrum Disorder (ASD) and status epilepticus, all based on THC and/or non-psychoactive CBD.
Additionally, SciSparc holds a controlling interest in a subsidiary that sells hemp seed oil-based products on the Amazon.com (NASDAQ:AMZN) Marketplace.
As a clinical-stage pharmaceutical company, SciSparc is led by a team of experienced executives and scientists dedicated to advancing cannabinoid pharmaceuticals.
The information in this article is based on a press release statement from SciSparc Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.